Selank Nootropic Research

01 What Is Selank?

Selank is a synthetic heptapeptide developed in the 1980s–90s at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences, principally by the team of Academician Vadim Ushakov. It is based on tuftsin — an endogenous tetrapeptide fragment of the immunoglobulin IgG heavy chain — with the addition of a Pro-Gly-Pro sequence that significantly enhances metabolic stability in plasma and brain tissue.

Unlike classical nootropics (racetams, cholinergics) or anxiolytics (benzodiazepines, SSRIs), Selank occupies an unusual pharmacological niche: it produces anxiolytic effects without sedation, cognitive impairment, or withdrawal in preclinical models, while simultaneously showing nootropic (memory-enhancing) and immunomodulatory properties. This combination has made it the subject of ongoing interest in the CNS and longevity research communities.

02 Mechanism of Action

Selank's pharmacology is multifaceted and not fully elucidated. Several key mechanisms have been characterised:

GABA-A Receptor Modulation

Electrophysiological studies demonstrated that Selank modulates GABA-A receptor sensitivity in a manner similar to benzodiazepines — potentiating GABAergic inhibitory tone — but without the direct binding to the benzodiazepine allosteric site. This distinction is critical: Selank does not produce the sedation, cognitive impairment, or physical dependence associated with benzodiazepine GABA-A modulation in animal studies.

BDNF & NGF Upregulation

Multiple studies have documented Selank-induced upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the hippocampus and frontal cortex. BDNF is a key mediator of synaptic plasticity, long-term potentiation (LTP), and memory consolidation — providing a plausible molecular substrate for Selank's reported cognitive effects.

Enkephalinase Inhibition

Selank inhibits enkephalin-degrading enzymes (enkephalinases), resulting in higher local concentrations of endogenous enkephalins in the CNS. Enkephalins modulate anxiety, pain, and mood via µ and δ opioid receptors, contributing to the anxiolytic effect.

Serotonin & Dopamine Modulation

Gene expression studies (microarray) in rodent brain tissue following Selank administration documented changes in expression of 84 genes related to serotonergic and dopaminergic neurotransmission, including upregulation of 5-HT1A receptor expression and modulation of dopamine transporter (DAT) activity.

03 Anxiolytic Research

Selank's anxiolytic properties are the most extensively studied aspect of its pharmacology, with consistent results across multiple anxiety paradigms.

Classical Anxiety Tests

In elevated plus maze (EPM), open field test (OFT), and light-dark box paradigms, Selank-treated rodents showed significantly increased open-arm exploration, reduced thigmotaxis, and greater centre time — classic indicators of reduced anxiety. Effect sizes were comparable to diazepam (0.5 mg/kg) in some protocols.

Benzodiazepine Withdrawal Model

A particularly striking finding: Selank administration during benzodiazepine withdrawal attenuated withdrawal-induced anxiety, seizure susceptibility, and mortality in rats — without reinstating benzodiazepine tolerance. This suggests Selank may share anxiolytic mechanisms with BZDs while avoiding dependence pathways.

Stress Models

In unpredictable chronic mild stress (UCMS) models, Selank reversed anhedonia, reduced corticosterone elevation, and normalised HPA axis reactivity. This HPA-normalising effect distinguishes it from anxiolytics that merely suppress anxiety symptoms without addressing neuroendocrine dysregulation.

04 Cognitive & Memory Research

Selank's nootropic profile is characterised by memory consolidation enhancement, not stimulatory effects — distinguishing it from amphetamine-class nootropics.

Memory Consolidation

In passive avoidance paradigms (a test of aversive memory consolidation), Selank improved memory trace retention in normal animals and significantly reversed scopolamine-induced amnesia. The BDNF upregulation provides a plausible LTP-dependent mechanism.

Attention & Information Processing

Human EEG studies (conducted in Russia) showed Selank administration increased theta and alpha power in frontal and temporal regions — brain oscillations associated with working memory and focused attention — without the beta-band desynchronisation characteristic of stimulants.

Absence of Cognitive Impairment

Unlike benzodiazepines, which impair procedural and declarative memory formation even at anxiolytic doses, Selank in equivalent anxiolytic doses either left memory performance unchanged or improved it — a critically important distinction for research models where anxiolytic treatment would otherwise confound memory endpoints.

05 Immune Modulation

Selank's tuftsin heritage makes immune modulation a core part of its pharmacological profile. Tuftsin is itself a potent immunostimulant — the Pro-Gly-Pro addition in Selank modifies but does not eliminate this activity.

Cytokine Regulation

Selank administration in rodent infection and inflammation models demonstrated modulation of IL-6, TNF-α, and IFN-γ cytokine levels. Rather than simple immunostimulation or suppression, Selank appears to normalise dysregulated cytokine profiles — down-regulating pro-inflammatory cytokines in excess (e.g. post-infection) while maintaining appropriate immune activation.

Influenza & Viral Models

In influenza infection models, Selank-treated animals showed improved survival, reduced viral load at peak infection, and faster resolution of inflammatory response. Interferons α and γ were elevated early in infection in treated animals, consistent with enhanced innate antiviral response.

Anxiolytic-Immune Axis

The convergence of Selank's anxiolytic and immunomodulatory effects is mechanistically coherent: chronic stress and anxiety suppress immune function via HPA axis → cortisol → lymphocyte suppression. By normalising HPA reactivity, Selank may restore immune competence in stress-compromised models — a potentially important effect in chronic stress research.

06 Selank vs Semax: Research Comparison

Selank and Semax are often discussed together as the two most researched Russian neuropeptides. Understanding their differences helps researchers select the appropriate compound for specific endpoints.

07 Clinical Data

Selank is unusual among research peptides in having genuine (if limited) clinical data from its Russian registration process.

Russian Clinical Trials

Phase II/III studies conducted for Russian registration included patients with generalised anxiety disorder (GAD) and mixed anxiety-depressive disorder. Selank nasal spray (0.15%, 250 µg/nostril) administered daily for 14 days showed:

• Significant reduction in Hamilton Anxiety Scale (HAM-A) scores vs placebo
• Improvement in Clinical Global Impression (CGI) ratings
• No significant sedation, cognitive impairment, or withdrawal at trial end
• Well-tolerated: adverse events limited to mild local nasal irritation

Limitations

These studies were conducted in Russia in the 1990s–2000s and have not been published in major Western peer-reviewed journals in their full form. Sample sizes were modest. Without Western replication in GCP-compliant settings, the clinical evidence remains preliminary.

08 Protocol Notes (Preclinical)

Dosing in Preclinical Studies

• Anxiolytic endpoint: 100–300 µg/kg SC or IP in rodents
• Memory endpoint: 300–500 µg/kg SC or IP
• Immune endpoint: 100–300 µg/kg SC, acute or 5-day course

Administration Routes

• Intranasal: Primary clinical route (registered formulation 0.15%); CNS bioavailability via olfactory route
• Subcutaneous (SC): Standard preclinical route
• Intraperitoneal (IP): Used in acute pharmacological challenge studies

Stability

Selank is a heptapeptide with reasonable metabolic stability due to the Pro-Gly-Pro tail. Lyophilised powder reconstituted in bacteriostatic water; store at 4°C (short-term) or −20°C. Stable for 3–6 months reconstituted at −20°C.

Selank vs Semax Stack Protocols

Researchers studying combined nootropic + anxiolytic effects have used concurrent Selank + Semax protocols. Neither peptide produces acute tolerance in rodent models, and their mechanisms (GABAergic/serotonergic vs melanocortinergic/BDNF) are complementary rather than additive at the same receptor.

09 Frequently Asked Questions